BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30077672)

  • 1. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
    Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
    Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
    Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
    J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
    Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
    Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
    Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
    Wen D; Liao T; Ma B; Qu N; Shi RL; Lu ZW; Wang YL; Wei WJ; Ji QH
    Cancer Med; 2018 Feb; 7(2):285-296. PubMed ID: 29341469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical and Molecular Analyses Focusing on Mesenchymal Cells in Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis.
    Takada N; Mussazhanova Z; Hirokawa M; Nakashima M; Miyauchi A
    Pathobiology; 2018; 85(5-6):300-303. PubMed ID: 30223266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.
    Cho SW; Kim YA; Sun HJ; Ahn HY; Lee EK; Yi KH; Oh BC; Park DJ; Cho BY; Park YJ
    J Clin Endocrinol Metab; 2014 Sep; 99(9):E1641-9. PubMed ID: 24848709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of cell-adhesion molecules in histological variants of papillary thyroid carcinoma.
    Andriescu EC; Căruntu ID; Giuşcă SE; Lozneanu L; Ciobanu Apostol DG
    Rom J Morphol Embryol; 2018; 59(3):721-727. PubMed ID: 30534810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases.
    Suster D; Michal M; Nishino M; Piana S; Bongiovanni M; Blatnik O; Hájková V; Ptáková N; Michal M; Suster S
    Mod Pathol; 2020 Sep; 33(9):1702-1711. PubMed ID: 32291398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.
    Šelemetjev S; Bartolome A; Išić Denčić T; Đorić I; Paunović I; Tatić S; Cvejić D
    Int J Exp Pathol; 2018 Apr; 99(2):87-94. PubMed ID: 29665129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma, a novel predictor for lymph node metastasis; possible morphological indicator of epithelial mesenchymal transition.
    Liu Z; Kakudo K; Bai Y; Li Y; Ozaki T; Miyauchi A; Taniguchi E; Mori I
    J Clin Pathol; 2011 Apr; 64(4):325-9. PubMed ID: 21296795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea.
    Ahn HY; Song RY; Ahn HS; Kim HS
    Cancer Res Treat; 2021 Oct; 53(4):1204-1212. PubMed ID: 33592140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
    Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
    J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage.
    Chen BK; Ohtsuki Y; Furihata M; Takeuchi T; Iwata J; Liang SB; Sonobe H
    Int J Oncol; 1999 Nov; 15(5):893-8. PubMed ID: 10536170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic and molecular features of cribriform morular variant of papillary thyroid carcinoma].
    Cui XJ; Zhao HO; Su P; Chen J; Zhang RY; Pan Y; Ouyang XM; Liu J; Zhang JQ; Yang Y; Yang R; Ding L; Liu ZY
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):354-359. PubMed ID: 29783802
    [No Abstract]   [Full Text] [Related]  

  • 19. SOX11 expression in a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma containing BRAF c.1799_1801delTGA and CTNNB1 c.133T>C mutations.
    Wong SBJ; Nga ME; Michal M; Vanecek T; Seet JE; Petersson F
    Virchows Arch; 2019 Oct; 475(4):519-525. PubMed ID: 31327063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Wnt/β-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer.
    Zhang J; Gill AJ; Issacs JD; Atmore B; Johns A; Delbridge LW; Lai R; McMullen TP
    Hum Pathol; 2012 Jul; 43(7):1044-50. PubMed ID: 22204713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.